

Supplemental Data:




Figure S1. Related to Figure 2. T cell activation following immunization and tumor induction. (A) SIY-specific immune response was measured by IFN- γ ELISpot in BP-SIY and BPC-SIY mice inoculated with MC57.SIY, 5 days or 60 days prior to the assay. As a control, littermates not injected with MC57.SIY, were used (Mean \pm SEM, n = 3, 4, 4, 5, 6, 5; left to right, pooled out of two independent experiments). (B) BP-SIY and BPC-SIY tumors were analyzed for the degree of T cell infiltration 6-8 weeks after tumor induction. Depicted is amount of CD3⁺ infiltrated T cells per gram of tumor (n = 4 and 6 for BP-SIY and BPC-SIY, respectively, data are representative for 3 experiments). The tumor weight at time of analysis was 1.94 g \pm 0.26 g for BP-SIY and 2.2 g \pm 0.3 g for BPC-SIY (mean \pm SD). Data are shown in mean with SEM; Box plots show median with 95th percentile, maximal deviation shown by error bars. Significance was assumed with p \leq 0.05, with ** \leq 0.01.




Figure S2. Related to Figure 3. T cell expansion following immunization and tumor induction. (A) Representative example of pentamer staining for SIY-specific T cells in the spleen of naive or immunized tumor-bearing BP-SIY and BPC-SIY mice, isolated at the end point of the experiment shown in Figure 2. (B-C) Statistical analysis of antigen-specific cells detectable within the spleen (B) and TdLN (C) assessed through SIY-specific pentamer staining at the end point of the experiment. Shown are mean with SEM and n numbers, corresponding to the experiment shown in Figure 3. Significance was assumed with $p \leq 0.05$, with * ≤ 0.05 .




Figure S3. Related to Figure 4. Behavior of adoptively transferred effector T β -catenin-negative and -positive tumors. (A, B) Representative example of T cell

motility analyses in (A) a BP-SIY tumor lesion and (B) a BPC-SIY tumor lesion; start position was normalized to 0. Spider plots are derived from the example Movie 1 and Movie 2. (C) Net-displacement of adoptively transferred T cell in β -catenin-negative and positive tumors. Net displacement was calculated from start and end points obtained from the total displacement/distance analysis (Figure 4 G) and displays the most linear distance traveled by a given T cell ($n= 357$ (BP-SIY) and 55 (BPC-SIY)). (D) The individual distances between tumor cell and T cell used to calculate the mean distance ($n= 126$ (BP-SIY) and 96 (BPC-SIY), pooled out of 20 images obtained from 3 independent experiments). We only assessed events with a distance of $50 \mu\text{m}$ or less. (E) Representative example of eradicated tumor lesion in BP-SIY tumor model after transfer of effector 2C T cells. Left, tumor lesion on day 2 post-transfer, bright-field, 4x and 25x magnification (top to bottom); right, same area on day 5 post-transfer. These images correspond to Movie S3. (F) Number of effector T cells present in spleen and TdLN three days post-adoptive transfer of 1×10^6 *in vitro* activated 2C T cells. Left panel shows percent within CD8^+ T cells and right panel depicts the total number of 2C T cells per gram tumor. Shown are mean with 95th percentile, $n = 4$ and 6 for BP-SIY and BPC-SIY, respectively. Data are shown in mean with SEM, box plots show median with 95th percentile, maximal deviation shown by error bars; significance was assumed with $p \leq 0.05$, with **** ≤ 0.0001 .

Movie S1. Related to Figure 4. Representative time-lapse of effector T cells migrating through BP-SIY (left) and BPC-SIY (right) tumor microenvironments acquired using a 25x emulsion lens (scale bar $10 \mu\text{m}$). YFP-positive tumor cells are pseudo-colored in green and effector T cells in red. Movies were acquired at a speed of 4.128 s/frame (14.5 frames/min) and are shown as 20 frames/s.

Movie S2. Related to Figure 4. MTrackJ analysis of T cell motility in Movie S1. Each line is tracking one T cell moving across the tumor (BP-SIY (left) and BPC-SIY (right); scale bar $10 \mu\text{m}$); YFP-positive tumor cells are pseudo-colored in green and effector T cells in red. Movies were acquired at a speed of 4.128 s/frame (14.5 frames/min) and are shown as 20 frames/s).

Movie S3. Related to Figure 4. Representative time-lapse of effector T cell migrating through BP-SIY at 48 hr (left) and 120 hr (right) after adoptive transfer (acquired using a 25x emulsion lens; scale bar $10 \mu\text{m}$; YFP-positive tumor cells are

pseudo-colored in green and effector T cells in red). Movies were acquired at a speed of 4.128 s/ frame (14.5 frames/min) and are shown as 20 frames/s. At 48 hr T cells engage close contact with tumor while at the 120 hr time-point the tumor was eradicated and T cell are patrolling.








Figure S4. Related to Figure 6. Adoptively transferred 2C T cells migrate into the TME in a chemokine-dependent manner. (A) Amount (number/gram tumor) of 2C T cells detectable after 72 h post transfer into BP-SIY (circle, n = 3) and BPC-SIY (square, n = 2) tumor or after transfer of 2C T cells, pretreated with pertussis toxin, into BP-SIY tumors (triangle, n = 3) or after transfer of P14 effector T cells into BP-SIY tumors (open triangle, n = 3). The tumor weight at time of analysis was 1.5 g \pm 0.2 g for BP-SIY + 2C, 1.8 g \pm 0.18 g for BP-SIY + 2C-PTX, 1.4 g \pm 0.12 g for BP-SIY + P14 and 1.2 g \pm 0.08 g for BPC-SIY + 2C (mean \pm SD). (B) Expression level of CXCL9 and CXCL10 in macrophages (M Φ ; CD45⁺, MHCII⁺, CD11c⁻, CD11b⁺), monocyte-derived DC (moDC; CD45⁺, MHCII⁺, CD11c⁺, CD11b^{high}), conventional DC (cDC; CD45⁺, MHCII⁺, CD11c⁺, CD11b^{dim}, CD103/CD8a⁻) and CD103⁺ DC (CD45⁺, MHCII⁺, CD11c⁺, CD11b^{dim}, CD103/CD8a⁺) assessed using qRT-PCR (n=3, cDC CXCL10 two samples were below detection level). (C-D) Protein expression of CXCL10 in CD103⁺ DC (CD45⁺, MHCII⁺, CD11c⁺, CD11b^{dim}, CD103/CD8a⁺) assessed using intracellular staining. (C) Depicts a representative staining in BP and BPC tumor-derived DC (pre-gated CD45⁺, MHCII⁺, CD11c⁺, CD11b^{dim}, CD103/CD8a⁺) and (D) depicts statistical analysis (n=5). The tumor weight at time of analysis was 1.2 g \pm 0.15 g for BP and 1.1 g \pm 0.2 g for BPC (mean \pm SD). (E) Chemokine expression profiling on CD103⁺ and CD103⁻ DC assessed from sorted DC via quantitative PCR analysis (n =4). The tumor weight at time of analysis across all experiments was 1.4 g \pm 0.1 g for BP and 2 g \pm 0.14 g for BPC (mean \pm SD). (F) Amount of conventional CD103⁻ DC found in tumors with control (GFP, grey circles) or *Ccr5*^{-/-} (black circles) bone marrow (n = 7 and 4, corresponding data to Figure 6 D and E). The tumor weight at time of analysis was 0.7 g \pm 0.08 g for control chimeras and 0.8 g \pm 0.2 g for *Ccr5*^{-/-} chimeras (mean \pm SD). Data are shown in mean with SEM, box plots show median with 95th percentile, maximal deviation shown by error bars; significance was assumed with p \leq 0.05, with * \leq 0.05; ** \leq 0.01; **** \leq 0.0001.








Figure S5. Related to Figure 7. *Batf3*-dendritic cell-derived CXCL10 is required for the recruitment of effector T cells into the tumor microenvironment.

(A) Percentage of adoptively transferred 2C T cells in total CD8 T cells detected in tumor, TdLN and spleen of BP-SIY mice engrafted with CD11c-DTR/WT (grey circles) or CD11c-DTR/*Batf3*^{-/-} (black circles) bone marrow and treated with diphtheria toxin. (B) Number (tumor, left) or percentage (TdLN and spleen, right) of CD103⁺ DC detectable after diphtheria toxin-depletion. Mice depicted in C and D are corresponding to mice shown in Figure 5F (n = 4). The tumor weight at time of analysis was 0.8 g ± 0.1 g for WT chimeras and 0.6 g ± 0.1 g for *Batf3*^{-/-} chimeras (mean ± SD). (C) Amount of adoptively transferred 2C effector T cells migrated into the tumor following intratumoral injection of WT (open) or *Cxcl10*^{-/-} (filled) FLT3-L derived DC into DT-depleted CD11c-DTR bone marrow chimeras on the BP-SIY background (n = 3). The tumor weight at time of analysis was 0.4 g ± 0.05 g for WT DC and 0.38 g ± 0.06 g for *Cxcl10*^{-/-} DC (mean ± SD). (D) Expression level of CXCL9 and CXCL10 in immature (iDC) and FLT3-L matured DC (FLT3-DC) of WT and *Cxcl10*^{-/-} (KO) bone-marrow derived DC, used in the experiment depicted in (C). # indicates samples with expression below detection limits. (E) Number of detected 2C effector T cell per gram of tumor in BP-SIY bone marrow chimeras reconstituted with WT or *Cxcl10*^{-/-} bone marrow (n = 6 /5). BPC-SIY mice engrafted with WT bone marrow were used as control (n = 3). The tumor weight at time of analysis was 0.35 g ± 0.05 g for BP-SIY WT, 0.5 g ± 0.1 g for BP-SIY *Cxcl10*^{-/-} and 0.6g ± 0.05 g for BPC-SIY WT (mean ± SD). Data are shown in mean with SEM, box plots show median with 95th percentile, maximal deviation shown by error bars; significance was assumed with p ≤ 0.05, with * ≤ 0.05; ** ≤ 0.01.